Weishuai Liu

Dr. Weishuai Liu

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 May 2023 in Drug Resistance Updates
Verified
Journal Article
Closed access
SWShuai Wang
Shuai Wang
LZLingyi Zhou
Lingyi Zhou
NJNing Ji
Ning Ji
CSChengtao Sun
Chengtao Sun
LSLinlin Sun
Linlin Sun
WLWei Lu
Wei Lu

28 September 2024 in Biological Procedures Online
Verified
Journal Article
Open access
PDF file
BWBin Wang
Bin Wang
YPYue Pan
Yue Pan
YXYongjie Xie
Yongjie Xie
CWCong Wang
Cong Wang
YYYinli Yang
Yinli Yang
ZPZhanyu Pan
Zhanyu Pan
Pancreatic cancer is a devastating malignancy with a high mortality rate, poor prognosis, and limited treatment options. The tumor microenvironment (TME) plays a crucial role in tumor progression and therapy resistance. Multiple subpopulations of cancer-associated fibroblasts (CAFs) within the TME can switch between different states, exhibiting both antitumorigenic and protumorigenic functions in pancreatic cancer. It seems that targeting fibroblast-related proteins and other stromal components is an appealing approach to combat pancreatic cancer. This study employed single-cell transcriptome sequencing to identify MME (Membrane Metalloendopeptidase)-expressing CAFs in pancreatic cancer. Systematic screening was conducted based on tumor differentiation, lymph node metastasis, and T-stage parameters to identify and confirm the existence of a subpopulation of fibroblasts termed MME+CAFs. Subsequent analyses included temporal studies, exploration of intercellular communication patterns focusing on the hypoxia signaling pathway, and investigation of MME+CAF functions in the pancreatic cancer microenvironment. The pathway enrichment analysis and clinical relevance revealed a strong association between high MME expression and glycolysis, hypoxia markers, and pro-cancer inflammatory pathways. The role of MME+CAFs was validated through in vivo and in vitro experiments, including high-throughput drug screening to evaluate potential targeted therapeutic strategies. Single-cell transcriptome sequencing revealed tumor-associated fibroblasts with high MME expression, termed MME+CAF, exhibiting a unique end-stage differentiation function in the TME. MME+CAF involvement in the hypoxia signaling pathway suggested the potential effects on pancreatic cancer progression through intercellular communication. High MME expression was associated with increased glycolysis, hypoxia markers (VEGF), and pro-cancer inflammatory pathways in pancreatic cancer patients, correlating with lower survival rates, advanced disease stage, and higher oncogene mutation rates. Animal experiments confirmed that elevated MME expression in CAFs increases tumor burden, promotes an immunosuppressive microenvironment, and enhances resistance to chemotherapy and immunotherapy. The developed MME+CAF inhibitor IOX2 (a specific prolyl hydroxylase-2 (PHD2) inhibitor), combined with AG (Paclitaxel + Gemcitabine) and anti-PD1 therapy, demonstrated promising antitumor effects, offering a translational strategy for targeting MME in CAFs of pancreatic cancer. The study findings highlighted the significant role of MME+CAF in pancreatic cancer progression by shaping the TME and influencing key pathways. Targeting MME presented a promising strategy to combat the disease, with potential implications for therapeutic interventions aimed at disrupting MME+CAF functions and enhancing the efficacy of pancreatic cancer treatments.

12 August 2025 in Genomics
Verified
Journal Article
Open access
XYXiaozhou Yu
Xiaozhou Yu
GSGuangcong Shen
Guangcong Shen
ZLZiyun Liu
Ziyun Liu
PKParhat Kaysar
Parhat Kaysar
XSXiaobin Shang
Xiaobin Shang
WLWeishuai Liu
Weishuai Liu
APOBEC (apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like) family-mediated mutagenesis is widespread in human cancers. However, we still have a limited understanding of the biological features and clinical relevance of APOBEC mutagenesis in cancer, particularly in pancreatic cancer. In this study, we conducted a comprehensive analysis of various data, including whole-exome sequencing (WES), targeted next-generation sequencing (NGS), transcriptome analysis (both bulk RNA-seq and single-cell RNA-seq), immune profiling, immune checkpoint blockade (ICB) response, patient survival, and drug sensitivity. We used various bioinformatics and statistical methods to uncover the distributional features, microenvironmental changes, and clinical significance of APOBEC mutagenesis in pancreatic adenocarcinoma (PAAD). APOBEC mutagenesis significantly influenced mutation patterns in PAAD. Higher enrichment scores of APOBEC mutagenesis signature (APMs) were associated with survival prognosis, immune remodeling, and potential responses to immune checkpoint blockade (ICB) in PAAD patients. In pancreatic cancer, APOBEC3A and APOBEC1 played important roles in malignant progression and cell differentiation in the tumor microenvironment and mediated enhanced CAF-tumor cell communication in the microenvironment, while APMs were also involved in the formation of an immunosuppressive microenvironment in pancreatic cancer through multiple pathways. Additionally, we developed and validated a machine learning model related to APOBEC mutagenesis across various cohorts of PAAD to predict poor survival prognosis. We also conducted drug sensitivity analyses to identify irinotecan as the drug with the highest inhibitory effect on APMs. Subsequently, in vitro experiments verified that irinotecan significantly inhibited pancreatic tumor cell proliferation. Our findings showed that irinotecan significantly reduced the proliferation, metastasis, and glycolysis of pancreatic tumor cells. It also decreased the expression levels of activation markers in cancer-associated fibroblasts (CAFs), including CD73, ACTA2, and COL1A1. In vivo experiments demonstrated that irinotecan could remodel the immune microenvironment by inhibiting Tregs, and combined with Treg inhibitors, it could effectively reduce the tumor burden of PAAD. Our study illustrated the characterization of APOBEC mutagenesis in multiple cancer types and highlighted its potential value as a prognostic and immunotherapeutic biomarker for PAAD, and finally demonstrated the effectiveness of irinotecan, an inhibitor of APMs, in vivo and in vitro experiments.